HD-OPM Archive
Topics › Inflammation & CRP

FDA approved low-dose colchicine for CV risk reduction, including multiple risk factors

Louis Nervegna · Jun 20, 2025 · ♥ 9 reactions · 1 comments · original Facebook post
Inflammation & CRPPCSK9, ezetimibe & newer drugsGuidelines, policy & public health
AI summary & key facts

Louis notes that the FDA approved low-dose colchicine to reduce cardiovascular events, working by lowering arterial inflammation. Per the Medscape report, it is the first specific anti-inflammatory drug for this purpose in people with established atherosclerotic disease or multiple risk factors.

Colchicine has full FDA approval to treat heart disease, even for primary prevention.

It works by lowering arterial inflammation.

#colchicineHD #inflammationHD #crpHD #fdaHD

Research cited

Shared from Gokhan Can · original post

Please note that the drug has been approved even for primary prevention with multiple risk factors.

← newer: Colchicine cut percent atheroma volume by over 1% in one yeaolder: Pilot: 20 g/day creatine raised brain creatine 11% in Alzhei →